Replies to post #118755 on Biotech Values

[DewDiligence]

ABT reiterated 2011 EPS guidance of $4.54-4.64, which makes the forward P/E a screaming buy at ~11x; moreover, the dividend yields 3.7%:

http://finance.yahoo.com/news/Abbott-Reports-174-Percent-prnews-4085838733.html?x=0&.v=1

Abbott is confirming ongoing [i.e. non-GAAP] earnings-per-share guidance for the full-year 2011 of $4.54 to $4.64. The midpoint of this guidance range reflects growth of 10 percent over 2010.

Abbott forecasts specified items for the full-year 2011 of approximately $0.84 per share, primarily associated with acquisition integration/cost reduction initiatives and in-process R&D. [This is the reconciliation between GAAP and non-GAAP EPS, which is detailed in ABT’s PR.]

…On Feb. 18, 2011, the board of directors of Abbott declared the company's quarterly common dividend of 48 cents per share, an increase of 9 percent over the prior year. The cash dividend is payable May 15, 2011, to shareholders of record at the close of business on April 14, 2011. This marks the 349th consecutive dividend paid by Abbott since 1924.

[masterlongevity]

do you know the WHAT 3 ALZ compounds they have in development ? MOA? i don't have any ABT compounds on my radar